TW201713613A - 新二氟酮醯胺衍生物 - Google Patents

新二氟酮醯胺衍生物 Download PDF

Info

Publication number
TW201713613A
TW201713613A TW105114334A TW105114334A TW201713613A TW 201713613 A TW201713613 A TW 201713613A TW 105114334 A TW105114334 A TW 105114334A TW 105114334 A TW105114334 A TW 105114334A TW 201713613 A TW201713613 A TW 201713613A
Authority
TW
Taiwan
Prior art keywords
substituted
methyl
difluoro
hexylamine
oxo
Prior art date
Application number
TW105114334A
Other languages
English (en)
Chinese (zh)
Inventor
貝諾伊特 賀恩斯伯格
羅伯特 伊康
艾瑞克A 奇塔
漢斯P 麥爾奇
麥可 路林格
彼得 莫爾
Original Assignee
赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 赫孚孟拉羅股份公司 filed Critical 赫孚孟拉羅股份公司
Publication of TW201713613A publication Critical patent/TW201713613A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
TW105114334A 2015-05-11 2016-05-09 新二氟酮醯胺衍生物 TW201713613A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15167151 2015-05-11

Publications (1)

Publication Number Publication Date
TW201713613A true TW201713613A (zh) 2017-04-16

Family

ID=53174868

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105114334A TW201713613A (zh) 2015-05-11 2016-05-09 新二氟酮醯胺衍生物

Country Status (8)

Country Link
US (1) US10428108B2 (fr)
EP (1) EP3294718B1 (fr)
JP (1) JP6757336B2 (fr)
CN (1) CN107531653B (fr)
AR (1) AR104856A1 (fr)
HK (1) HK1245258A1 (fr)
TW (1) TW201713613A (fr)
WO (1) WO2016180751A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019507176A (ja) 2016-03-04 2019-03-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Htra1阻害剤としての新規ジフルオロケタミド誘導体
EP3423469A1 (fr) 2016-03-04 2019-01-09 H. Hoffnabb-La Roche Ag Nouveaux dérivés de trifluorométhylpropanamide utilisés comme inhibiteurs de htra1
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
US10730832B2 (en) * 2016-06-21 2020-08-04 Orion Ophthalmology LLC Aliphatic prolinamide derivatives
KR102595723B1 (ko) * 2016-06-21 2023-10-27 오리온 옵탈몰로지 엘엘씨 헤테로시클릭 프롤린아미드 유도체
EP3484859B1 (fr) * 2016-07-18 2021-09-15 F. Hoffmann-La Roche AG Nouveaux dérivés de difluorocétamide en tant qu'inhibiteurs de htra1
EP3504193A1 (fr) 2016-08-23 2019-07-03 H. Hoffnabb-La Roche Ag Nouveaux dérivés de difluorocétamide en tant qu'inhibiteurs de htra1
CN109563084A (zh) 2016-08-23 2019-04-02 豪夫迈·罗氏有限公司 作为htra1抑制剂的新型三氟甲基丙酰胺衍生物
CN115594734B (zh) * 2021-09-09 2023-03-17 广东众生睿创生物科技有限公司 酮酰胺衍生物及其应用

Also Published As

Publication number Publication date
CN107531653A (zh) 2018-01-02
EP3294718A1 (fr) 2018-03-21
HK1245258A1 (zh) 2018-08-24
CN107531653B (zh) 2021-10-19
JP2018516892A (ja) 2018-06-28
EP3294718B1 (fr) 2020-04-29
WO2016180751A1 (fr) 2016-11-17
JP6757336B2 (ja) 2020-09-16
US20180057526A1 (en) 2018-03-01
US10428108B2 (en) 2019-10-01
AR104856A1 (es) 2017-08-23

Similar Documents

Publication Publication Date Title
TW201713613A (zh) 新二氟酮醯胺衍生物
JP6836996B2 (ja) 新しいトリフルオロメチルプロパンアミド誘導体
CN107614505B (zh) 作为双重atx/ca抑制剂的新型二环化合物
TW200836743A (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
TW201416362A (zh) 1-(環烷基羰基)脯胺酸衍生物
JPH08500361A (ja) タキキニン拮抗薬
CA2150992A1 (fr) Antagonistes cyclohexyliques du recepteur de la tachykinine
AU2016223072A1 (en) Selective BACE1 inhibitors
TW200404060A (en) Fused heterocyclic compounds
JP2019532077A (ja) 治療用化合物及びその使用方法
JP2019513698A (ja) Htra1阻害剤としての新規なトリフルオロメチルプロパンアミド誘導体
EP3423467B1 (fr) Nouveaux dérivés de diflurokétamide comme inhibiteurs de la htra1
US20110009379A1 (en) Indolinone compound
JP2020517710A (ja) Nm23活性剤を含む癌転移抑制用医薬組成物
US10865182B2 (en) Difluoroketamide derivatives as HtrA1 inhibitors
EP3504197B1 (fr) Nouveaux dérivés de trifluorométhylpropanamide utilisés comme inhibiteurs de htra1
JP2019526563A (ja) Htra1阻害剤としての新規ジフルオロケタミド誘導体
EP4377295A1 (fr) Haloacéthydrazides utiles en tant qu'inhibiteurs d'aep
TW202000651A (zh) 治療性組成物及其使用方法